Eiger To Close After GLP-1 Antagonist Gambit Fails
The company had pivoted towards a drug with the opposite mechanism to Novo Nordisk’s Wegovy, but ran out of time and money.
The company had pivoted towards a drug with the opposite mechanism to Novo Nordisk’s Wegovy, but ran out of time and money.